S

Shandong Boan Biotechnology Co Ltd
HKEX:6955

Watchlist Manager
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Watchlist
Price: 8.08 HKD -5.94% Market Closed
Market Cap: 4.3B HKD
Have any thoughts about
Shandong Boan Biotechnology Co Ltd?
Write Note

Shandong Boan Biotechnology Co Ltd
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Boan Biotechnology Co Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Other Receivables
ÂĄ16.9m
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Receivables
ÂĄ685.6m
CAGR 3-Years
55%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Receivables
ÂĄ92.2m
CAGR 3-Years
36%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Other Receivables
ÂĄ185.2m
CAGR 3-Years
-12%
CAGR 5-Years
-9%
CAGR 10-Years
21%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Receivables
ÂĄ8m
CAGR 3-Years
-17%
CAGR 5-Years
-34%
CAGR 10-Years
-23%
Imeik Technology Development Co Ltd
SZSE:300896
Other Receivables
ÂĄ24.8m
CAGR 3-Years
17%
CAGR 5-Years
39%
CAGR 10-Years
N/A
No Stocks Found

Shandong Boan Biotechnology Co Ltd
Glance View

Market Cap
4.1B HKD
Industry
Biotechnology

Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.

Intrinsic Value
12.91 HKD
Undervaluation 37%
Intrinsic Value
Price
S

See Also

What is Shandong Boan Biotechnology Co Ltd's Other Receivables?
Other Receivables
16.9m CNY

Based on the financial report for Dec 31, 2023, Shandong Boan Biotechnology Co Ltd's Other Receivables amounts to 16.9m CNY.

What is Shandong Boan Biotechnology Co Ltd's Other Receivables growth rate?
Other Receivables CAGR 3Y
-18%

Over the last year, the Other Receivables growth was 16%. The average annual Other Receivables growth rates for Shandong Boan Biotechnology Co Ltd have been -18% over the past three years .

Back to Top